NRG Oncology/GOG Studies
- Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer.
- Few FDA approved options exist for the treatment of recurrent ovarian cancer. In patients with recurrent disease, re-treatment with paclitaxel using a weekly schedule has demonstrated activity, possibly through anti-angiogenic as well as direct cytotoxic mechanisms . Gynecologic Oncology Group (GOG)-0126N demonstrated a 21% objective response rate (and a 46% rate of stable disease) in this population .
- Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing cells to transit rapidly through mitosis.
- To estimate the probability of complete clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma, and to evaluate the value of inhibin for predicting response.